Stable performance during Covid In Elekta's second quarter, we managed to perform better than the overall radiotherapy market both in terms of orders and revenue despite continuous challenging circumstances. We also improved margins and stabilized cash flow. The launch of our new Harmony linac and regulatory clearances enhanced our product portfolio and strengthened our ability to deliver on our strategy of Precision Radiation Medicine. Gustaf Salford President and CEO
1After continuous investments.
2稀释前/稀释后。
三基于固定货币。
# # #
For further information, please contact:
Cecilia Ketels,投资者关系主管
电话:+46 76 611 76 25,电子邮箱:塞西莉亚·凯特尔斯@电子科技
时区:CET:中欧时间
Johan Adebäck,Elekta AB代理首席财务官(公共)
电话:+46 70 873 33 21,电子邮件:约翰·阿德巴克@电子科技
时区:CET:中欧时间
根据欧盟市场滥用条例,Elekta AB(publ)有义务公开这些信息。该信息于2020年11月26日07:30提交出版。(雷格马尔)
关于Elekta
For almost five decades, Elekta has been a leader in precision radiation medicine. Our more than 4,000 employees worldwide are committed to ensuring everyone in the world with cancer has access to – and benefits from – more precise, personalized radiotherapy treatments. Headquartered in Stockholm, Sweden, Elekta is listed on NASDAQ Stockholm Exchange. Visit elekta.com or follow @Elekta on Twitter.
塞西莉亚·凯特尔斯, Head of Investor Relations
电话:+46 76 611 76 25,
电子邮件:塞西莉亚·凯特尔斯@电子科技
时区:CET:中欧时间
约翰·阿德巴克,代理首席财务官,Elekta AB(publ)
Tel: +46 70 873 33 21,
电子邮件:johan.adeback@elekta.com
时区:CET:中欧时间